Nuvalent, Inc. Class A (NUVL)
NASDAQ:NUVL
Want to see NUVL full AI Analyst Report?
Top Page
Nuvalent
(NASDAQ:NUVL)
Select Model
Select Model
Rating:52Neutral
Price Target:
$94.00
▼(-12.65% Downside)
Action:Reiterated
Date:06/02/26
The score is primarily held back by significant ongoing losses and heavy cash burn with no revenue base yet, partially offset by a strong, debt-free balance sheet. Technicals are mixed (positive momentum but below key moving averages), while valuation remains challenging due to unprofitability. A positive FDA filing provides an incremental upside catalyst.
Positive Factors
Balance sheet strength
A debt-free balance sheet with sizable equity provides durable financial flexibility to fund multi-year clinical programs and regulatory review periods. This reduces refinancing urgency, supports continued R&D investment, and improves viability through the typical clinical-to-commercial inflection timeline.
Negative Factors
Pre-revenue with widening losses
Being pre-revenue while net losses have expanded materially increases dependence on external capital. Without product sales, the company must bridge clinical development to approval, leaving long-term profitability and shareholder returns uncertain until commercialization occurs.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
A debt-free balance sheet with sizable equity provides durable financial flexibility to fund multi-year clinical programs and regulatory review periods. This reduces refinancing urgency, supports continued R&D investment, and improves viability through the typical clinical-to-commercial inflection timeline.
Read all positive factors
Nuvalent (NUVL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.12B
Dividend YieldN/A
Average Volume (3M)716.84K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue GrowthN/A
EPS Growth-37.66%
CountryUS
Employees162
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-6.06
Shares Outstanding73,562,660
10 Day Avg. Volume1,043,553
30 Day Avg. Volume716,842
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)5.86
Price to Sales (P/S)0.00
P/FCF Ratio-26.57
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-21.95
Forecast
1Y Price Target
$141.60Price Target Upside31.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-5.7
Revenue Forecast (FY)$11.67M
Nuvalent Business Overview & Revenue Model
Company Description
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinas...
How the Company Makes Money
Nuvalent is a clinical-stage company and, as of publicly available information up to my knowledge cutoff (2025-09), does not have approved commercial products. As a result, it does not generate recurring product sales revenue; its operations are p...
Nuvalent Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -362.61M | -10.48M | 0.00 | -126.22M | -86.11M | -45.82M |
| Net Income | -450.07M | -425.38M | -260.76M | -126.22M | -81.85M | -46.34M |
Balance Sheet | ||||||
| Total Assets | 1.33B | 1.41B | 1.14B | 732.38M | 482.46M | 293.82M |
| Cash, Cash Equivalents and Short-Term Investments | 1.29B | 1.37B | 1.12B | 719.90M | 472.16M | 288.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 156.78M | 164.37M | 71.96M | 31.82M | 19.48M | 8.79M |
| Stockholders Equity | 1.17B | 1.25B | 1.07B | 700.56M | 462.98M | 285.04M |
Cash Flow | ||||||
| Free Cash Flow | -312.79M | -275.21M | -185.06M | -99.74M | -64.97M | -40.00M |
| Operating Cash Flow | -312.79M | -275.21M | -185.06M | -99.74M | -64.97M | -40.00M |
| Investing Cash Flow | -168.91M | -124.08M | -573.51M | -143.53M | -10.66M | -220.03M |
| Financing Cash Flow | 520.59M | 515.34M | 568.88M | 336.85M | 248.92M | 318.22M |
Nuvalent Technical Analysis
Negative
107.61
Price Trends
102.59
Negative
102.44
Negative
97.60
Negative
Market Momentum
-2.06
Positive
40.18
Neutral
12.29
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUVL, the sentiment is Negative. The current price of 107.61 is above the 20-day moving average (MA) of 101.69, above the 50-day MA of 102.59, and above the 200-day MA of 97.60, indicating a bearish trend. The MACD of -2.06 indicates Positive momentum. The RSI at 40.18 is Neutral, neither overbought nor oversold. The STOCH value of 12.29 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUVL.
Nuvalent Risk Analysis
Nuvalent disclosed 90 risk factors in its most recent earnings report. Nuvalent reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nuvalent Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $6.14B | 12.68 | 87.36% | ― | 81.26% | 1079.73% | |
54 Neutral | $208.18M | -3.25 | -29.67% | ― | ― | ― | |
52 Neutral | $7.12B | -16.43 | -42.78% | ― | ― | -37.66% | |
52 Neutral | $8.80B | -10.74 | 139.66% | ― | 450.60% | -28.90% | |
52 Neutral | $12.02B | -62.94 | -260.01% | ― | 63.88% | 35.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
NUVL
Nuvalent
94.02
16.00
20.51%
CYTK
Cytokinetics
72.29
39.99
123.81%
TGTX
TG Therapeutics
40.56
0.50
1.25%
AXSM
Axsome Therapeutics
231.48
119.57
106.84%
RNA
Atrium Therapeutics, Inc.
12.30
-2.45
-16.61%
Nuvalent Corporate Events
Product-Related AnnouncementsRegulatory Filings and Compliance
Nuvalent Files FDA Application for Lung Cancer Therapy
Positive
Apr 7, 2026
On April 7, 2026, Nuvalent, Inc. reported that it had submitted a New Drug Application to the U.S. Food and Drug Administration for neladalkib, a treatment candidate for patients with tyrosine kinase inhibitor pre-treated advanced ALK-positive non...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.